# Antimicrobial Susceptibility Profiles of Commensal Enterococcus spp. Isolates from Turkeys in Hungarian Poultry Farms Between 2022 and 2023

**Authors:** Ádám Kerek, Ábel Szabó, Franciska Barnácz, Bence Csirmaz, László Kovács, Ákos Jerzsele

PMC · DOI: 10.3390/antibiotics14040331 · Antibiotics · 2025-03-21

## TL;DR

This study analyzed antibiotic resistance in Enterococcus bacteria from turkeys in Hungary, finding high resistance to several drugs and emphasizing the need for ongoing monitoring.

## Contribution

The study provides new antimicrobial susceptibility data for commensal Enterococcus spp. in turkeys, highlighting resistance trends and their public health implications.

## Key findings

- Resistance to amoxicillin was low (11.1%), but high resistance was observed for tylosin (62.6%), florfenicol (51.1%), doxycycline (48.7%), and enrofloxacin (45.5%).
- Vancomycin resistance reached 15.5%, consistent with global trends and indicating potential dissemination of resistance genes.
- Neomycin resistance levels in turkey isolates were comparable to those in human E. faecalis strains.

## Abstract

Background: Antimicrobial resistance (AMR) has become a serious global challenge in the 21st century. Poultry, including turkeys, are a vital source of animal-derived protein worldwide. Commensal bacterial strains in poultry can act as reservoirs for AMR, making monitoring them crucial for both veterinary and public health. Enterococcus species are emerging pathogens, particularly in severe nosocomial infections. Methods: This study aimed to assess the resistance profiles of commensal Enterococcus strains isolated (n = 470) from large-scale turkey flocks in Hungary. From each animal, two swab samples were collected: one from the oropharyngeal region near the tracheal entrance and one from the cloaca. The samples were subsequently processed, and the minimum inhibitory concentration (MIC) was determined following the Clinical and Laboratory Standards Institute (CLSI) guidelines. The tested antibiotics included amoxicillin, amoxicillin–clavulanic acid, imipenem, neomycin, doxycycline, florfenicol, tylosin, enrofloxacin, potentiated sulfonamide, vancomycin, ceftriaxone, spectinomycin, tiamulin, lincomycin, and colistin. The dilution range for MIC determination was set between 512 and 0.001 µg/mL. Results: Resistance to amoxicillin, a first-line treatment for Enterococcus infections, was low (11.1%). However, high resistance levels were observed for tylosin (62.6%), florfenicol (51.1%), doxycycline (48.7%), and enrofloxacin (45.5%). Notably, vancomycin resistance reached 15.5%, a finding consistent with global trends. Compared to human-derived Enterococcus data, resistance to aminopenicillins was significantly lower in turkey isolates, while neomycin resistance levels were comparable to those observed in human E. faecalis strains. Conclusions: The findings underscore the necessity of continuous surveillance of AMR trends in poultry production. While amoxicillin remains an effective treatment, the presence of multidrug-resistant strains and vancomycin-resistant isolates raises concerns regarding the potential dissemination of resistance genes. Future studies should incorporate next-generation sequencing to elucidate the genetic mechanisms underlying resistance. Additionally, integrating antibiotic usage data from farms may provide further insights into resistance dynamics. Strengthening antibiotic stewardship programs and fostering collaboration between veterinary and human medicine are crucial steps in addressing AMR under the One Health framework.

## Linked entities

- **Chemicals:** amoxicillin (PubChem CID 33613), amoxicillin–clavulanic acid (PubChem CID 6435924), imipenem (PubChem CID 104838), neomycin (PubChem CID 8378), doxycycline (PubChem CID 54671203), florfenicol (PubChem CID 114811), tylosin (PubChem CID 5280440), enrofloxacin (PubChem CID 71188), vancomycin (PubChem CID 14969), ceftriaxone (PubChem CID 5479530), spectinomycin (PubChem CID 15541), tiamulin (PubChem CID 656958), lincomycin (PubChem CID 3000540), colistin (PubChem CID 5311054)

## Full-text entities

- **Diseases:** nosocomial infections (MESH:D003428), Enterococcus infections (MESH:D007239)
- **Chemicals:** amoxicillin-clavulanic acid (MESH:D019980), spectinomycin (MESH:D000198), doxycycline (MESH:D004318), enrofloxacin (MESH:D000077422), aminopenicillins (-), neomycin (MESH:D009355), amoxicillin (MESH:D000658), florfenicol (MESH:C035534), tiamulin (MESH:C014224), ceftriaxone (MESH:D002443), vancomycin (MESH:D014640), lincomycin (MESH:D008034), tylosin (MESH:D015645), imipenem (MESH:D015378)
- **Species:** Meleagris gallopavo (common turkey, species) [taxon 9103], Homo sapiens (human, species) [taxon 9606], Enterococcus faecalis (species) [taxon 1351]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12024081/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12024081/full.md

## References

73 references — full list in the complete paper: https://tomesphere.com/paper/PMC12024081/full.md

---
Source: https://tomesphere.com/paper/PMC12024081